Exclusive: Forbion-backed cardio biotech rebrands to RyCarma with Phase 2 plans
A 20-year-old biotech working on small molecule treatments for cardiovascular and skeletal muscle diseases has rebranded and plans to enter Phase 2 in heart failure later this year. Formerly known as...
View ArticleHighlander Health acquires Target RWE to improve clinical trials
Highlander Health, the clinical trial startup co-founded by former Verily execs Amy Abernethy and Brad Hirsch, is acquiring data company Target RWE. Launched in September, Highlander wants to make it...
View ArticleKen Song's Candid licenses a T cell engager from WuXi Bio
Candid Therapeutics is committing up to $925 million for the rights to a trispecific T cell engager candidate developed by WuXi Biologics, further expanding its autoimmune disease pipeline. WuXi is...
View ArticleVertex signs in vivo gene editing delivery pact for sickle cell and...
Vertex Pharmaceuticals signed a three-year deal with Orna Therapeutics to use the RNA biotech’s delivery particles to develop its next iteration of gene editing treatments for sickle cell disease and...
View ArticleProfluent debuts AI model for CRISPR gene editing design
Bay Area biotech Profluent has taken another step in using AI to design new CRISPR gene editing systems, CEO Ali Madani exclusively told Endpoints News. The startup posted a preprint Monday ...
View ArticleExclusive: Avenzo picks up another ADC, this time with multi-partnered...
Avenzo Therapeutics, a well-funded biotech that has in-licensed treatment candidates from Chinese drug developers, has forged its third deal since reassembling much of the Turning Point Therapeutics...
View ArticleXyloCor raises $67.5M Series B, updates pivotal gene therapy trial plans
XyloCor Therapeutics has closed a $67.5 million Series B round to fund mid-stage development of its cardiac gene therapy. Two years ago, the biotech said it hoped its next trials of the ...
View ArticleJ&J's combo beats Tagrisso on survival in first-line lung cancer
Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival in a Phase 3 trial, notching a key win in its rivalry against the...
View ArticleMetsera’s long-acting GLP-1 looks competitive in Phase 2 obesity study
Data from a mid-stage obesity trial of Metsera’s long-acting injectable GLP-1 agonist suggest it could be competitive with approved incretins and several investigational compounds. The Phase 2a trial...
View ArticleNovo Nordisk partners with Variant Bio; Aviceda raises $207M in Series C
Plus, news about Alebund Pharmaceuticals, Capsida Biotherapeutics, CytomX Therapeutics and Generation Bio: Novo Nordisk’s latest obesity partner: The Danish pharma giant is teaming up with a small...
View ArticlePfizer extends AI drug discovery pact with PostEra, adding ADCs to deal
Pfizer has re-upped its drug discovery deal with AI startup PostEra to develop small molecule drugs and new warheads for antibody-drug conjugates, a major area of focus for the drugmaker following its...
View ArticleImmuneering touts positive pancreatic cancer data for MEK inhibitor
Immuneering’s shares rocketed in premarket trading on Tuesday on the back of positive mid-stage data for its MEK inhibitor in pancreatic cancer, sparking plans to add more combination arms. Three out...
View ArticleCompounding pharmacies face an uphill battle in fight over tirzepatide
Eli Lilly has officially waded into a legal battle between a trade group for large compounding facilities, a small compounding pharmacy and the FDA, after a Texas federal court granted ...
View ArticleBWX Technologies to buy Canadian isotope maker for $525M
This year's first radiopharmaceutical deal is slated to expand BWX Technologies’ presence in the North American nuclear tech market as demand is expected to creep up. Virginia-headquartered BWX...
View ArticleCalico, Denali's ALS drugs miss primary objectives in basket study
A basket study for experimental ALS treatments recorded a pair of additional failures on Monday from two prominent companies. New data from Google’s longevity play Calico and the neuro-focused biotech...
View ArticleDrugmakers cut list prices for some cancer, asthma and diabetes treatments
Bayer’s Nexavar and Boehringer Ingelheim's Spiriva are among a handful of drugs with reduced US list prices for the new year, according to a Tuesday analysis that showed average prices growing ...
View ArticleFDA sets an efficacy threshold for new weight loss drugs
New anti-obesity drugs should meet a minimum level of weight loss to be considered for approval, the FDA said Tuesday, taking the rare step of proposing an efficacy threshold for future products. In a...
View ArticleAetna takes Takeda to court over 'anticompetitive scheme' with generic drugs
Aetna is going after another pharmaceutical company for alleged price fixing. The health insurance provider filed suit against Takeda on Friday over what it says was an “anticompetitive scheme” to keep...
View ArticleNumber of FDA product adcomms last year returned to 2022 levels
The FDA held 13 advisory committee panels last year to discuss specific product applications, half the total in 2023 and compared with nine in 2022. The review by Endpoints News included all advisory...
View ArticleSanofi partners with Alloy Therapeutics to make new CNS drug
Sanofi has enlisted drug discovery company Alloy Therapeutics to develop an antisense oligonucleotide drug for a single, undisclosed central nervous system target. Sanofi will pay Alloy up to $27.5...
View Article